Changes in the levels and activities of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), have been described in a number of neurodegenerative disorders, including Huntington disease, Alzheimer disease and Parkinson disease. It is only in Huntington disease, however, that gain-of-function and loss-of-function experiments have linked BDNF mechanistically with the underlying genetic defect. Altogether, these studies have led to the development of experimental strategies aimed at increasing BDNF levels in the brains of animals that have been genetically altered to mimic the aforementioned human diseases, with a view to ultimately influencing the clinical treatment of these conditions. In this article, we will review the current knowledge about the involvement of BDNF in a number of neurodegenerative diseases, with particular emphasis on Huntington disease, and will provide the rationale for and discuss the problems in proposing BDNF treatment as a beneficial and feasible therapeutic approach in the clinic.
Brain-derived neurotrophic factor (BDNF) levels are reduced in the brains of patients with Alzheimer disease, Parkinson disease and Huntington disease
Data on BDNF in individuals affected by Alzheimer disease or Parkinson disease require further validation
Experiments performed in a range of Huntington disease animal models and in human tissue show reduced cortical BDNF mRNA and protein levels with respect to controls
BDNF trafficking is reduced in the presence of the Huntington disease mutation in experiments conducted in vitro
A mechanistic link has been established between wild-type huntingtin and gene transcription and intracellular transport of BDNF
Strategies for 'BDNF therapies' include upregulating BDNF levels by gene or protein delivery, or through small molecules targeting BDNF production, and increasing BDNF signaling using BDNF mimetics
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bibel, M. & Barde, Y. A. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 14, 2919–2937 (2000).
Binder, D. K. & Scharfman, H. E. Brain-derived neurotrophic factor. Growth Factors 22, 123–131 (2004).
Phillips, H. S. et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7, 695–702 (1991).
Murer, M. G., Yan, Q. & Raisman-Vozari, R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 3, 71–124 (2001).
Tapia-Arancibia, L., Aliaga, E., Silhol, M. & Arancibia, S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res. Rev. 59, 201–220 (2008).
Murer, M. G. et al. An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. Neuroscience 88, 1015–1032 (1999).
Narisawa-Saito, M., Wakabayashi, K., Tsuji, S., Takahashi, H. & Nawa, H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 7, 2925–2928 (1996).
Peng, S., Wuu, J., Mufson, E. J. & Fahnestock, M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem. 93, 1412–1421 (2005).
Lee, J. et al. Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Exp. Neurol. 194, 91–96 (2005).
Burbach, G. J. et al. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J. Neurosci. 24, 2421–2430 (2004).
Ando, S. et al. Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. J. Neurosci. Res. 70, 519–527 (2002).
Jones, K. R., Fariñas, I., Backus, C. & Reichardt, L. F. Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell 76, 989–999 (1994).
Ernfors, P., Kucera, J., Lee, K. F., Loring, J. & Jaenisch, R. Studies on the physiological role of brain-derived neurotrophic factor and neurotrophin-3 in knockout mice. Int. J. Dev. Biol. 39, 799–807 (1995).
Mesulam, M. M. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24, 521–529 (1999).
Binder, D. K., Croll, S. D., Gall, C. M. & Scharfman, H. E. BDNF and epilepsy: too much of a good thing? Trends Neurosci. 24, 47–53 (2001).
Kohno, R. et al. BDNF is induced by wild-type α-synuclein but not by the two mutants, A30P or A53T, in glioma cell line. Biochem. Biophys. Res. Commun. 318, 113–118 (2004).
Porritt, M. J., Batchelor, P. E. & Howells, D. W. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp. Neurol. 192, 226–234 (2005).
Baquet, Z. C., Bickford, P. C. & Jones, K. R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J. Neurosci. 25, 6251–6259 (2005).
Fumagalli, F., Racagni, G., Colombo, E. & Riva, M. A. BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice. Mol. Psychiatry 8, 898–899 (2003).
The Huntington's disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971–983 (1993).
Reiner, A. et al. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl Acad. Sci. USA 85, 5733–5737 (1988).
Rosas, H. D. et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65, 745–747 (2005).
Altar, C. A. et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389, 856–860 (1997).
Baquet, Z. C., Gorski, J. A. & Jones, K. R. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 24, 4250–4258 (2004).
Ferrer, I., Goutan, E., Marín, C., Rey, M. J. & Ribalta, T. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 866, 257–261 (2000).
Zuccato, C. et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493–498 (2001).
Zuccato, C. & Cattaneo, E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 81, 294–330 (2007).
Zuccato, C. et al. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 18, 225–238 (2008).
Zuccato, C. et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genet. 35, 76–83 (2003).
Zuccato, C. et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J. Neurosci. 27, 6972–6983 (2007).
Pruunsild, P., Kazantseva, A., Aid, T., Palm, K. & Timmusk, T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90, 397–406 (2007).
Shimojo, M. Huntingtin regulates RE1-silencing transcription factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSF-interacting LIM domain protein (RILP) and dynactin p150Glued. J. Biol. Chem. 283, 34880–34886 (2008).
Marullo, M. et al. Analysis of the repressor element-1 silencing transcription factor/neuronal-restrictive silencer factor occupancy of non-neuronal genes in peripheral lymphocytes from patients with Huntington's Disease. Brain Pathol. doi:10.1111/j.1750-3639.2008.00249.x
Gauthier, L. R. et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127–138 (2004).
Colin, E. et al. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J. 27, 2124–2134 (2008).
Zala, D. et al. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum. Mol. Genet. 17, 3837–3846 (2008).
Her, L. S. & Goldstein, L. S. Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J. Neurosci. 28, 13662–13672 (2008).
Strand, A. D. et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J. Neurosci. 27, 11758–11768 (2007).
Canals, J. M. et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with encephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24, 7727–7739 (2004).
Alberch, J. et al. Association between BDNF Val66Met polymorphism and age at onset in Huntington disease. Neurology 65, 964–965 (2005).
Di Maria, E. et al. No evidence of association between BDNF gene variants and age-at-onset of Huntington's disease. Neurobiol. Dis. 24, 274–279 (2006).
Kishikawa, S. et al. Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease. Neurobiol. Dis. 24, 280–285 (2006).
Mai, M. et al. No association between polymorphisms in the BDNF gene and age at onset in Huntington disease. BMC Med. Genet. 7, 79 (2006).
Metzger, S. et al. Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. Hum. Genet. 120, 285–292 (2006).
Croll, S. D. et al. Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex. Neuroscience 93, 1491–1506 (1999).
Arancibia, S. et al. Protective effect of BDNF against β-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol. Dis. 31, 316–326 (2008).
Selkoe, D. J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein. J. Alzheimers Dis. 3, 75–80 (2001).
Nagahara, A. H. et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 15, 331–337 (2009).
Levivier, M., Przedborski, S., Bencsics, C. & Kang, U. J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 15, 7810–7820 (1995).
Isacson, O. et al. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat. Med. 1, 1189–1194 (1995).
Hung, H. C. & Lee, E. H. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression. Brain Res. Mol. Brain Res. 41, 14–26 (1996).
Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O. & Hashimoto, N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 37, 733–741 (1995).
Deierborg, T., Soulet, D., Roybon, L., Hall, V. & Brundin, P. Emerging restorative treatments for Parkinson's disease. Prog. Neurobiol. 85, 407–432 (2008).
Beal, M. F. et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168–171 (1986).
Kells, A. P., Henry, R. A. & Connor, B. AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment. Gene Ther. 15, 966–977 (2008).
Davies, S. W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537–548 (1997).
Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55–66 (1998).
Zala, D. et al. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol. Dis. 20, 785–798 (2005).
Gharami, K., Xie, Y., An, J. J., Tonegawa, S. & Xu, B. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem. 105, 369–379 (2008).
Cho, S. R. et al. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J. Clin. Invest. 117, 2889–2902 (2007).
Gines, S. et al. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur. J. Neurosci. 23, 649–658 (2006).
Ginsberg, S. D., Che, S., Wuu, J., Counts, S. E. & Mufson, E. J. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J. Neurochem. 97, 475–487 (2006).
Connor, B. et al. Trk receptor alterations in Alzheimer's disease. Brain Res. Mol. Brain Res. 42, 1–17 (1996).
The BDNF Study Group Phase III. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 52, 1427–1433 (1999).
Ochs, G. et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 201–206 (2000).
Gill, S. S. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589–595 (2003).
Hacein-Bey-Abina, S. et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132–3142 (2008).
Biffi, A. & Naldini, L. Gene therapy of storage disorders by retroviral and lentiviral vectors. Hum. Gene Ther. 16, 1133–1142 (2005).
Yáñez-Muñoz, R. J. et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12, 348–353 (2006).
Emerich, D. F. et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 386, 395–399 (1997).
Rossi, F. & Cattaneo, E. Opinion: neural stem cell therapy for neurological diseases: dreams and reality. Nat. Rev. Neurosci. 3, 401–409 (2002).
Pardridge, W. M. Molecular trojan horses for blood-brain barrier drug delivery. Discov. Med. 6, 139–143 (2006).
Longo, F. M. et al. Small molecule neurotrophin receptor ligands: novel strategies for for targeting Alzheimer's disease mechanisms. Curr. Alzheimer Res. 4, 503–506 (2007).
Mattson, M. P., Chan, S. L. & Duan, W. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol. Rev. 82, 637–672 (2002).
Spires, T. L. & Hannan, A. J. Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw. FEBS J. 272, 2347–2361 (2005).
Maswood, N. et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101, 18171–18176 (2004).
Fumagalli, F., Racagni, G. & Riva, M. A. The expanding role of BDNF: a therapeutic target for Alzheimer's disease? Pharmacogenomics J. 6, 8–15 (2006).
Fumagalli, F., Racagni, G. & Riva, M. A. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics J. 6, 95–104 (2006).
Duan, W. et al. Sertraline slows disease progression and increases neurogenesis in N171–82Q mouse model of Huntington's disease. Neurobiol. Dis. 30, 312–322 (2008).
Rigamonti, D. et al. Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators. J. Biol. Chem. 282, 24554–24562 (2007).
Borrell-Pagès, M. et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116, 1410–1424 (2006).
Tuszynski, M. H. et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11, 551–555 (2005).
Chang, Q., Khare, G., Dani, V., Nelson, S. & Jaenisch, R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49, 341–348 (2006).
Koch, P., Opitz, T., Steinbeck, J. A., Ladewig, J. & Brüstle, O. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc. Natl Acad. Sci. USA 106, 3225–3230 (2009).
Sun, Y. et al. Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture. Mol. Cell Neurosci. 38, 245–258 (2008).
Bagnoli, S. et al. Brain-derived neurotrophic factor genetic variants are not susceptibility factors to Alzheimer's disease in Italy. Ann. Neurol. 55, 447–448 (2004).
Nishimura, A. L. et al. Lack of association between the brain-derived neurotrophin factor (C-270T) polymorphism and late-onset Alzheimer's disease (LOAD) in Brazilian patients. J. Mol. Neurosci. 22, 257–260 (2004).
Bodner, S. M. et al. Genetic variation in the brain derived neurotrophic factor gene in Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134B, 1–5 (2005).
Vepsäläinen, S. et al. Genetic analysis of BDNF and TrkB gene polymorphisms in Alzheimer's disease. J. Neurol. 252, 423–428 (2005).
Chuu, J. Y. et al. The brain-derived neurotrophic factor Val66Met polymorphism and rate of decline in Alzheimer's disease. J. Alzheimers Dis. 9, 43–49 (2006).
Saarela, M. S. et al. No association between the brain-derived neurotrophic factor 196 G>A or 270 C>T polymorphisms and Alzheimer's or Parkinson's disease. Folia Neuropathol. 44, 12–16 (2006).
Huang, R., Huang, J., Cathcart, H., Smith, S. & Poduslo, S. E. Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease. J. Med. Genet. 44, e66 (2007).
Schjeide, B. M. et al. Assessment of Alzheimer's disease case-control associations using family-based methods. Neurogenetics 10, 19–25 (2008).
Kunugi, H. et al. A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. Mol. Psychiatry 6, 83–86 (2001).
Riemenschneider, M. et al. A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease in patients lacking the Apolipoprotein E ε4 allele. Mol. Psychiatry 7, 782–785 (2002).
Tsai, S. J. et al. Association analysis of brain-derived neurotrophic factor Val66Met polymorphisms with Alzheimer's disease and age of onset. Neuropsychobiology 49, 10–12 (2004).
Desai, P., Nebes, R., DeKosky, S. T. & Kamboh, M. I. Investigation of the effect of brain-derived neurotrophic factor (BDNF) polymorphisms on the risk of late-onset Alzheimer's disease (AD) and quantitative measures of AD progression. Neurosci. Lett. 379, 229–234 (2005).
Akatsu, H. et al. Variations in the BDNF gene in autopsy-confirmed Alzheimer's disease and dementia with Lewy bodies in Japan. Dement. Geriatr. Cogn. Disord. 22, 216–222 (2006).
Matsushita, S. et al. Brain-derived neurotrophic factor gene polymorphisms and Alzheimer's disease. J. Neural Transm. 112, 703–711 (2005).
Nishimura, M., Kuno, S., Kaji, R. & Kawakami, H. Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer's disease, Parkinson's disease, and multiple system atrophy. Mov. Disord. 20, 1031–1033 (2005).
Olin, D., MacMurray, J. & Comings, D. E. Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism. Neurosci. Lett. 381, 275–278 (2005).
Cozza, A. et al. SNPs in neurotrophin system genes and Alzheimer's disease in an Italian population. J. Alzheimers Dis. 15, 61–70 (2008).
Hashimoto, R. et al. Effect of the BDNF and the ApoE polymorphisms on disease progression in preclinical Alzheimer's disease. Genes Brain Behav. 8, 43–52 (2008).
Håkansson, A. et al. Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population. Ann. Neurol. 53, 823 (2003).
Hong, C. J. et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset. Neurosci. Lett. 353, 75–77 (2003).
Liu, Q. R. et al. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134B, 93–103 (2005).
Xiromerisiou, G. et al. BDNF tagging polymorphisms and haplotype analysis in sporadic Parkinson's disease in diverse ethnic groups. Neurosci. Lett. 415, 59–63 (2007).
Chen, C. M. et al. Nuclear receptor NR4A2 IVS6 +18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 458–462 (2007).
Momose, Y. et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol. 51, 133–136 (2002).
Toda, T. et al. Toward identification of susceptibility genes for sporadic Parkinson's disease. J. Neurol. 250 (Suppl. 3), iii40–iii43 (2003).
Parsian, A., Sinha, R., Racette, B., Zhao, J. H. & Perlmutter, J. S. Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease. Parkinsonism Relat. Disord. 10, 213–219 (2004).
Karamohamed, S. et al. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology 65, 1823–1825 (2005).
Laske, C. et al. Decreased brain-derived neurotrophic factor (BDNF)- and β-thromboglobulin (β-TG)- blood levels in Alzheimer's disease. Thromb. Haemost. 96, 102–103 (2006).
Laske, C. et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J. Neural Transm. 113, 1217–1224 (2006).
Laske, C. et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J. Psychiatr. Res. 41, 387–394 (2007).
Leyhe, T. et al. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 258, 124–128 (2008).
Conforti, P. et al. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol. Cell Neurosci. 39, 1–7 (2008).
Ciammola, A. et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 574–577 (2007).
The work of the authors described in this Review was supported by the Huntington Disease Society of America (USA), Telethon (Italy), the Hereditary Disease Foundation (USA), the HighQ/CHDI Foundation (USA), Fondazione Cariplo (Italy), Ministero dell'Istruzione dell'Università e della Ricerca (Italy), Ministero della Salute (Italy), NeuroNE (Sixth Framework Programme, European Union, LSHM-CT-2004-512039) and STEM-HD (Sixth Framework Programme, European Union, LSHB-CT-2006-037349) (E. Cattaneo) and by Conferenza dei Rettori delle Università Italiane (Italy) (C. Zuccato).
The authors declare no competing financial interests.
About this article
Cite this article
Zuccato, C., Cattaneo, E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5, 311–322 (2009). https://doi.org/10.1038/nrneurol.2009.54
Mitochondria Homeostasis and Oxidant/Antioxidant Balance in Skeletal Muscle—Do Myokines Play a Role?
Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS)
Molecular Psychiatry (2021)
Treatment of ischemic neuronal death by introducing brain-derived neurotrophic factor mRNA using polyplex nanomicelle